We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

34 hedge funds and large institutions have $117M invested in Milestone Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $339K

0% more funds holding

Funds holding: 34 → 34 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

0.96% less ownership

Funds ownership: 68.99% → 68.03% (-0.96%)

15% less capital invested

Capital invested by funds: $138M → $117M (-$20.4M)

Holders
34
Holders Change
–
Holders Change %
0%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
10
Closed
5
Calls
$2.68M
Puts
$339K
Net Calls
+$2.34M
Net Calls Change
+$2.09M

Top Buyers

1
Barclays
Barclays
United Kingdom
+$875K
2
BC
Boxer Capital
California
+$695K
3
O
OrbiMed
New York
+$664K
4
Renaissance Technologies
Renaissance Technologies
New York
+$384K
5
PVI
Pura Vida Investments
New York
+$129K

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$1.7M
2
Morgan Stanley
Morgan Stanley
New York
-$927K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$783K
4
RCM
RA Capital Management
Massachusetts
-$594K
5
AFM
Anson Funds Management
Texas
-$336K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$25M – – –
O
2
OrbiMed
New York
$15M +$664K +90,712 +4%
BC
3
Boxer Capital
California
$14.9M +$695K +95,000 +4%
NHAS
4
Novo Holdings A/S
Denmark
$14.7M – – –
RCM
5
RA Capital Management
Massachusetts
$13M -$594K -81,211 -3%
IC
6
Ikarian Capital
Texas
$10.6M – – –
SCM
7
Suvretta Capital Management
New York
$4.93M – – –
Morgan Stanley
8
Morgan Stanley
New York
$4.93M -$927K -126,699 -13%
Millennium Management
9
Millennium Management
New York
$4.16M +$14.7K +2,011 +0.3%
PVI
10
Pura Vida Investments
New York
$2.71M +$129K +17,640 +4%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$1.55M -$783K -106,960 -29%
Renaissance Technologies
12
Renaissance Technologies
New York
$1.25M +$384K +52,400 +32%
BFM
13
Boothbay Fund Management
New York
$1.21M – – –
Barclays
14
Barclays
United Kingdom
$909K +$875K +119,561 +320%
JGC
15
J. Goldman & Co
New York
$581K -$38.3K -5,235 -5%
SFI
16
Susquehanna Fundamental Investments
Pennsylvania
$351K -$129K -17,658 -23%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$336K +$42.5K +5,800 +11%
Two Sigma Investments
18
Two Sigma Investments
New York
$317K -$19K -2,598 -5%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$290K – – –
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$222K +$117K +15,961 +71%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$120K +$14K +1,914 +10%
TD Asset Management
22
TD Asset Management
Ontario, Canada
$108K -$31.9K -4,361 -19%
State Street
23
State Street
Massachusetts
$99K – – –
UBS Group
24
UBS Group
Switzerland
$78K -$8.39K -1,147 -8%
Goldman Sachs
25
Goldman Sachs
New York
$70K -$75K -10,246 -46%
1
2

MIST Hedge Fund Activity: Q1 2021 in Review

34 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2021, worth a combined $117M — down 15% from $138M a quarter earlier.

Fund positioning in MIST was balanced in Q1 2021: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 10 trimmed.

The largest buyer was Barclays, adding an estimated $875K. The largest seller was Tekla Capital Management, exiting entirely with an estimated $1.7M sold.

  • 34 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $117M of Milestone Pharmaceuticals stock for Q1 2021, down 15% quarter-over-quarter.
  • 5 funds opened new Milestone Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of 0 holders.
  • The largest Milestone Pharmaceuticals buyer in Q1 2021 was Barclays, an estimated $875K added.
  • The largest Milestone Pharmaceuticals seller in Q1 2021 was Tekla Capital Management, an estimated $1.7M sold.

Based on aggregated 13F filings for Q1 2021.